CoreCap Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-1,401
| Closed | -$44K | – | 3194 |
|
|
2026
Q2 | $44K | Sell |
1,401
-399
| -22% | -$11.8K | ﹤0.01% | 1459 |
|
|
2026
Q1 | $44.6K | Sell |
1,800
-450
| -20% | -$10.7K | ﹤0.01% | 1359 |
|
|
2025
Q4 | $52.5K | Sell |
2,250
-125
| -5% | -$2.78K | ﹤0.01% | 1317 |
|
|
2025
Q3 | $46.8K | Sell |
2,375
-25,006
| -91% | -$514K | ﹤0.01% | 1351 |
|
|
2025
Q2 | $594K | Sell |
27,381
-6,861
| -20% | -$162K | 0.02% | 472 |
|
|
2025
Q1 | $830K | Sell |
34,242
-1,638
| -5% | -$36.9K | 0.04% | 371 |
|
|
2024
Q4 | $749K | Buy |
35,880
+35,480
| +8,870% | +$762K | 0.03% | 382 |
|
|
2024
Q3 | $7.95K | Hold |
400
| – | – | ﹤0.01% | 1858 |
|
|
2024
Q2 | $6.2K | Sell |
400
-300
| -43% | -$4.67K | ﹤0.01% | 1138 |
|
|
2024
Q1 | $11.2K | Buy |
+700
| New | +$10.5K | ﹤0.01% | 1707 |
|
|
2023
Q3 | – | Sell |
-14,913
| Closed | -$200K | – | 564 |
|
|
2023
Q2 | $200K | Buy |
+14,913
| New | +$215K | 0.01% | 536 |
|
|
2022
Q4 | $160K | Buy |
+8,612
| New | +$133K | 0.01% | 588 |
|
|
2022
Q1 | – | Sell |
-6,000
| Closed | -$41K | – | 850 |
|
|
2021
Q4 | $41K | Buy |
+6,000
| New | +$39.5K | ﹤0.01% | 1064 |
|
Other funds holding CPRX
CoreCap Advisors's CPRX Position: Q3 2026 in Review
CoreCap Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 1,401 shares — an estimated $44K sold.
CoreCap Advisors first reported a position in CPRX in Q4 2021 and held it in 13 quarters. The position peaked at $830K in Q1 2025. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.
- CoreCap Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- CoreCap Advisors sold 1,401 Catalyst Pharmaceutical shares in Q3 2026, an estimated $44K.
- CoreCap Advisors first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 13 quarters.
- CoreCap Advisors's Catalyst Pharmaceutical position peaked at $830K in Q1 2025.
- 1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.